What's Hot
View all perspectives
Janet Pope
1 year ago
#vasculitis clinical trials are accelerating. Need the right time - early studies have lessons learned re feasibility and design/endpoints #ACR23 @RheumNow @ACRheum Great lecture - P Merkel 15W127 great graphs of vasculitis developments https://t.co/YRdPiaflxY
Aurelie Najm
1 year ago
New MoA in RA 🚨
Dual inhibition BAFF/BLys Telalicept MTX IR pts Ph3 vs. PBO
ACR20 60 vs. 27%
ACR50 21 vs. 6%
DAS28<3.2 15 vs. 5%
Less Rx prog
Safety similar infection rates
@RheumNow #ACR23 ABSTL20 https://t.co/WHysLSKyo0
Richard Conway
1 year ago
Serrano-Combarro et al. JAKi in RA-ILD. 73 patients on JAKi (74% Bari). Many had prev received abatacept/rituximab. HRCT improved/stable in 76%. Dyspnoea stable/improved in 95%. Abstr#2174 #ACR23 @RheumNow https://t.co/j6SiEzSRif
Richard Conway
1 year ago
Long-term abatacept in UIP RA-ILD. 233 patients, median 22 month follow-up. Sustained benefits to previous data. ABA was withdrawn in 50 patients (21.5%) (ILD worsening 20, joint worsening 15, serious infections 7, others 8) Abstr#2165 #ACR23 @RheumNow https://t.co/SinE4GgFRE https://t.co/M1Nnce58OE
Aurelie Najm
1 year ago
Knee OA, to inject or not to inject: the great debate 📣
A thread👇🏼👇🏼👇🏼
Maglette Klotenburg argues in favor, with moderation
IA GC improves pain
Repetitive injections can be harmful
@RheumNow #ACR23 https://t.co/3p4UVLngpx
Md Yuzaiful Md Yusof
1 year ago
#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest https://t.co/Rj1k1z0Tsz
Janet Pope
1 year ago
In case you missed it!
AR882-selective oral URAT1i added to #allopurinol rapidly improves/dissolve #tophi. Given with #colchicine,
#placebo 3/4 flared vs <1/2 w drug.
My critique is why not optimize allopurinol dose - only 300 mg, no fuboxastat
L15 #ACR23 @RheumNow @ACRheum https://t.co/NZWLpWXT51
Richard Conway
1 year ago
Window of opportunity for abatacept in RA-ILD. Early treated patients (<6 months vs >2 years) appear to do better in terms of FVC. Abstr#2173 #ACR23 @RheumNow https://t.co/14IsA1KbAk https://t.co/ZbZEwzaOu0
Eric Dein
1 year ago
Q for Rheumatologists:
How often do you counsel appropriate SLE patients about cervical ca screening and/or vaccination?
Re: PAPILUP Study A#1479 #ACR23 - shows PAP findings of HR-HPV+abnml cytology comparable to HIV+ pts
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD
1 year ago
L20 @ #ACR23
New therapy on the horizon for RA pts that failed MTX?
⭐️Telitacicept = recombinant fusion protein targeting & neutralizing BLyS & APRIL
➡️ placebo-controlled, phase III trial, 24w
👉at wk 24, PBO pts switched to drug arm for 24 more wks
➡️ 479 pts w/… https://t.co/94MyC8sdaG https://t.co/x3MUmFJPK6
Janet Pope
1 year ago
What happens when you stop #steroids and/ immunosuppressive Rx in Pts in remission for at least 1 yr in #IgG4 disease?
You are likely guessing correctly
Pts flare! Don’t stop Rx
?taper 🤷♀️
Like RA Rx - if stop Rx = flares
Large RCT from China L16 #ACR23 @RheumNow @RheumNow
Janet Pope
1 year ago
Agimeteran a TLR7/8i 30 mg in #cutaneous #lupus which differentiated from placebo. Small single site #RCT. Far more pts improved #CLASI by 50% vs PBO #ACR23 #ACRbest @RheumNow @ACRheum L15 In larger RCT now! https://t.co/zssjgpydVY
Janet Pope
1 year ago
#IA Injection in #knee #OA.
TLC599 vs #dexamethasone vs saline #RCT-blinded.
Both active #Rx better than #PBO. Some differences in average daily pain between active drugs.
Not sure where it may fit in? After IA steroid failure?
L18 #ACR23 @ACRheum @RheumNow https://t.co/rLh6ISBpUw
sheila
1 year ago
Inflammation in interstitial fibrosis & tubular atrophy (i-IFTA) is assoc w/ GFR loss accdg to this study by Dr SMalvica et al.
✳️In pts w/ mod-to-severe IFTA, the degree of i-IFTA was assoc'd with higher risk of GFR loss
#ACR23 ABST2552 @RheumNow https://t.co/7iA0nzbmgM
Richard Conway
1 year ago
Bastard et al. 12,071 French PsA. Low incidence serious infections on advanced therapy - 17 per 1,000 person-years. Significantly lower risk ETN (HR 0.70), UST (HR 0.56) vs ADA. Others similar. Abstr#2566 #ACR23 @RheumNow https://t.co/GGDvRxP9ht https://t.co/Ol7G1OG73t
Poster Hall